Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Oncotheryeon, Inc., OncoMed Pharmaceuticals, Inc., and Array BioPharma Inc. Stocks Jumped Today

By Dan Carroll - Jul 23, 2014 at 2:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Three biotechs climb after a competitor's trial success boosts hope across the HER-2 breast cancer treatment market

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Oncothyreon (NASDAQ: ONTY), a developmental biotech, climbed more than 13% today, while fellow biotech stocks OncoMed ( OMED ) and Array BioPharma ( ARRY ) roared higher by as much as 10% and 16.4%, respectively, following a positive trial result from Puma Biotechnology's HER2-positive breast cancer therapy neratinib.

So What: Neratinib's astronomical success in a phase 3 trial for increasing disease-free survival in early stage HER2-positive breast cancer by 33 % as compared to a placebo as sent shock waves throughout the biotech industry. Wall Street's pushed stocks of fellow clinical-stage HER2-positive breast cancer drug developers higher on the day in light of the positive trial data. Array and Oncothyreon collaborate on ARRY-380, a phase 1 candidate for treating the disease, while OncoMed is developing vantictumab, which last year launched a phase 1b trial targeting HER2-positive breast cancer. OncoMed did

Now What: Puma might be looking to file for approval next year for neratinib after the success, but OncoMed, Oncothyreon, and Array are in much earlier-stage trials for their own HER2-positive cancer treatments. Still, the strong showing by neratinib has lifted confidence across the biotech sector that agents specifically targeting the HER2 growth factor have a major place as a lucrative adjuvant treatment.

While OncoMed, Oncothyreon, and Array still have a long way to go to showing similar gains from their own therapies, this is a market worth pursuing: Analysts have pegged neratinib as racking up $4 billion or more in peak sales if cleared by the FDA, with an 85% chance at regulatory approval.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Array Technologies, Inc. Stock Quote
Array Technologies, Inc.
ARRY
OncoMed Pharmaceuticals, Inc. Stock Quote
OncoMed Pharmaceuticals, Inc.
OMED

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/06/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.